Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder

NCT06951854 is registered in ClinicalTrials.gov with Neuroventi Inc. as lead sponsor.

NCT NCT06951854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06951854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
Lead sponsor
Neuroventi Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2025
Completion date
December 1, 2026
Enrollment
105 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder (asd